Daxor Corporation (DXR, Financial) has unveiled pivotal research findings from Duke University Medical Center, which have been featured in the prestigious American Heart Journal. The study explores how Blood Volume Analysis (BVA) can accurately measure red blood cell mass and effectively distinguish between true anemia and dilutional anemia in heart failure patients.
Leading this research, Dr. Veraprapas Kittipibul shared critical insights: A significant portion of heart failure patients suffer from anemia, which BVA can help classify. Among those diagnosed with anemia according to the World Health Organization's hemoglobin criteria, 60% had true anemia while 40% experienced dilutional pseudo-anemia. It was observed that patients with dilutional pseudo-anemia were more likely to be hospitalized for heart failure compared to those with no anemia or true anemia. However, variations in red blood cell mass (RBCM) profiles did not significantly impact hospitalization rates for heart failure. Patients with RBCM deficits or true anemia were found to have reduced exercise capacity.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Daxor Corp (DXR, Financial) is $25.00 with a high estimate of $25.00 and a low estimate of $25.00. The average target implies an upside of 247.22% from the current price of $7.20. More detailed estimate data can be found on the Daxor Corp (DXR) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Daxor Corp's (DXR, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Daxor Corp (DXR, Financial) in one year is $2.78, suggesting a downside of 61.39% from the current price of $7.2. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Daxor Corp (DXR) Summary page.
